



## **Guidelines for Medication Use:**

### **Drugs for the Management of Gaucher's Disease**

#### **Imiglucerase (Cerezyme)**

##### **Background:**

Type 1 Gaucher's Disease is caused by a deficiency of glucocerebrosidase, an enzyme responsible for the degradation of glycosphingolipid glucosylceramide, resulting in widespread pathological effects. Affected organs include the liver, spleen, and bone marrow. Consequences of Gaucher's Disease include hepatosplenomegaly, anemia, thrombocytopenia, and osteonecrosis with pathological fractures.

Imiglucerase is produced by recombinant DNA technology and is an analogue of human beta glucocerebrosidase.

##### **Administration:**

Cerezyme is administered by IV infusion.

##### **Criteria for approval:**

1. Cerezyme should be prescribed by a physician knowledgeable in the management of Gaucher's Disease.
2. Candidates for Cerezyme should be at least 18 years of age with a documented diagnosis of Type 1 Gaucher's Disease.

##### **Authorization Procedure:**

1. All courses of Cerezyme therapy require prior authorization.
2. Cerezyme is intended for IV administration. If administered by IV infusion, Cerezyme would be covered under the SummaCare medical benefit.
3. Initial Authorizations will be for a maximum of six months' therapy. If continued response is exhibited at six months, authorization will be provided for up to 12 months.
4. The prescriber should complete a Pharmacy Authorization Form and fax to Pharmacy Benefit Management at (330) 996-8580 or call the Pharmacy Authorization Line at (330) 996-8805.

5. Walgreens Specialty Pharmacy shall be the preferred provider of Cerezyme if the provider does not buy and bill.
6. The prescriber and member will be notified of authorization or denial as delineated in the SummaCare Pharmacy Benefit Management policies and procedures.

**Approved: SummaCare Pharmacy & Therapeutics Committee: January 5, 2006**

**Revised: November 1, 2007**

**Reviewed: May 1, 2008**

---

Medical Director

---

Pharmacy Director

**References:**

Drug Facts and Comparisons. Wolters Kluwer Health, Inc. October 2003

Cerezyme Prescribing Information. Genzyme Corporation. April 2005.